Abstract
The ENHANCE study will assess the effect of ezetimibe plus simvastatin in patients with heterozygous familial hypercholesterolaemia. Carotid artery intima-media thickness will be measured, which is able to predict a progression to cardiovascular or cerebrovascular events. The SEAS study will evaluate whether treatment with ezetimibe and simvastatin, compared with placebo, will reduce the risk of major cardiovascular events in patients with aortic stenosis. The SHARP study will measure major vascular events in patients with chronic kidney disease or who are receiving dialysis. Ezetimibe and simvastatin treatment will be compared with placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The British Journal of Diabetes & Vascular Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
